Form 4: InMed Pharmaceuticals COO Exercises Stock Options
SEC Form 4 Filing
Michael Woudenberg, Chief Operating Officer of InMed Pharmaceuticals, exercised employee stock options on May 27, 2024.
Summary
- Michael Woudenberg, the Chief Operating Officer of InMed Pharmaceuticals Inc., exercised employee stock options on May 27, 2024.
- The transaction involved the exercise of options for 394 common shares.
- The exercise price was $263.18 per option, converted from a Canadian dollar price of C$358.875 using an exchange rate of C$1.3636.
- Following the transaction, Woudenberg directly owns 75,100 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports a standard transaction (stock option exercise) without indicating positive or negative implications for the company.
Industry Context
This is a routine disclosure related to executive compensation and stock option exercises, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 05/27/2019 | Date exercisable for employee stock options |
| 05/27/2024 | Date of transaction: Exercise of employee stock options and expiration date of employee stock options |
| 05/28/2024 | Date of signature for the Form 4 filing |
Keywords
InMed Pharmaceuticals, Stock Options, Form 4, Woudenberg, Chief Operating Officer, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.